David L. Barker, PhD
Dr. David L. Barker currently serves on the Boards of Directors of AmideBio and Singular Genomics Systems, and is Board Member and Chairman at Integrated Diagnostics and BioNano Genomics.
Dr. Barker is a board member of the non-profit foundation Summit for Stem Cell, which supports research toward an autologous dopamine neuron replacement therapy for Parkinson’s disease.
Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.
In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.
Darren Cai, PhD
Dr. Cai has served on our board of directors since September 2014. From April 2015 to April 2018, Dr. Cai served as a Managing Director of Legend Capital, a Chinese early stage and expansion stage venture capital firm, and held a previous position as a Director of Legend Capital from October 2012.
Mr. Junfeng Wang has served on our board of directors since February 2018.
Albert Luderer, PhD
Albert Luderer has three decades of experience in biotechnology, with special focuses on technology, business development and commercialization.
Dr. Luderer previously served as president and CEO of BioTrove, a venture-backed molecular biological tools company that was acquired by Life Technologies. Additionally, Dr. Luderer was CEO of venture-backed therapeutics company Light Sciences and president and COO of bioMérieux, Inc.
Senior management positions at Dianon Systems (LabCorp), Boehringer Mannheim (Roche), and Corning round out Dr. Luderer’s experience in the industry. He earned his PhD from Rutgers University, where he was a National Science Foundation predoctoral fellow, and performed postgraduate work in immunology at Jefferson Medical College.
Mr. Zhou has served on our board of directors since February 2018. Since April 2016, Mr. Zhou has served as an Executive Director at Legend Capital, and held previous positions as Director from April 2015 and Vice President from October 2012.
Christopher J. Twomey
Christopher J. Twomey has served on our board of directors since July 2018. Since August 2013, Mr. Twomey has served as a director and Chairman of the Audit Committee of Tandem Diabetes Care, Inc., a medical device company.